ReviewMayo Clinic proceedings2014
Breakthroughs in cell therapy for heart disease: focus on cardiosphere-derived cells.
Review in Mayo Clinic proceedings, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 54 citations in OpenAlex.
- Reductions in myocardial interstitial fibrosis are dissociated from LV chamber stiffness in swine with repetitive pressure overload.American journal of physiology. Heart and circulatory physiology · 2026Article
- Bioengineered Cellular and Acellular Therapies for Ischemic Heart Disease in Clinically Relevant Models.Bioengineering (Basel, Switzerland) · 2026Review
- A Novel In Vitro Potency Assay Demonstrating the Anti-Fibrotic Mechanism of Action of CDCs in Deramiocel.Biomedicines · 2025Article
- Cardiac Repair and Clinical Outcomes of Stem Cell Therapy in Heart Failure: A Systematic Review and Meta-Analysis.Diseases (Basel, Switzerland) · 2025Review
- Deconstructing Regenerative Medicine: From Mechanistic Studies of Cell Therapy to Novel Bioinspired RNA Drugs.Circulation research · 2024Review
- RNA and the emerging potential of bio-inspired molecules in cardiovascular disease therapies.European heart journal · 2024Article
- Degradable Biocompatible Porous Microtube Scaffold for Extended Donor Cell Survival and Activity.ACS biomaterials science & engineering · 2023Article
- Biodistribution of unmodified cardiosphere-derived cell extracellular vesicles using single RNA tracing.Journal of extracellular vesicles · 2022Article
- Article
- Application of stem cell-derived exosomes in ischemic diseases: opportunity and limitations.Journal of translational medicine · 2021Review
- Minimally invasive delivery of therapeutic agents by hydrogel injection into the pericardial cavity for cardiac repair.Nature communications · 2021Article
- Stem Cell-Derived Exosomes Potential Therapeutic Roles in Cardiovascular Diseases.Frontiers in cardiovascular medicine · 2021Review
- Stem cell therapy for muscular dystrophies.The Journal of clinical investigation · 2020Review
- N-cadherin overexpression enhances the reparative potency of human-induced pluripotent stem cell-derived cardiac myocytes in infarcted mouse hearts.Cardiovascular research · 2020Article
- Y RNAs: Biogenesis, Function and Implications for the Cardiovascular System.Advances in experimental medicine and biology · 2020Review
- Progenitor Cells Derived from Drain Waste Product of Open-Heart Surgery in Children.Journal of clinical medicine · 2019Article
- Therapeutic angiogenesis using stem cell-derived extracellular vesicles: an emerging approach for treatment of ischemic diseases.Stem cell research & therapy · 2019Review
- Definition of a cell surface signature for human cardiac progenitor cells after comprehensive comparative transcriptomic and proteomic characterization.Scientific reports · 2019Article
- Cardiac cell-integrated microneedle patch for treating myocardial infarction.Science advances · 2018Article
- A mechanistic roadmap for the clinical application of cardiac cell therapies.Nature biomedical engineering · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The clinical reality of cell therapy for heart disease dates back to the 1990 s, when autologous skeletal myoblasts were first transplanted into failing hearts during open-chest surgery. Since then, the focus has shifted to bone marrow-derived cells and, more recently, cells extracted from the heart itself. Although progress has been nonlinear and often disheartening, the field has nevertheless made remarkable progress. Six major breakthroughs are notable: (1) the establishment of safety with intracoronary delivery; (2) the finding that therapeutic regeneration is possible; (3) the increase in allogeneic cell therapy; (4) the effect of increasing mechanistic insights; (5) glimmers of clinical efficacy; and (6) the progression to phase 2 and 3 studies. This article individually reviews these landmark developments in detail and concludes that the field has reached a new phase of maturity where the prospect of clinical impact is increasingly imminent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.